Zydus Lifesciences Limited Press Release Feb 20 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA for its pharmaceutical products. The first approval is for Gabapentin Tablets, which are indicated for managing Postherpetic Neuralgia, and will be manufactured at their facility in Moraiya.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 17 2023
- Press Release Feb 15 2023
- Press Release Jan 27 2023
- Press Release Jan 16 2023
- Press Release Jan 12 2023
Later from Zydus Lifesciences
- Press Release Feb 24 2023
- Press Release Feb 28 2023
- Press Release Mar 02 2023
- Press Release Mar 03 2023
- Press Release Mar 07 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences